EWTX - Edgewise Therapeutics initiates phase 2 trial of muscle wasting therapy in kids

• Edgewise Therapeutics ( NASDAQ: EWTX ) on Thursday said it had started a phase 2 trial of its molecule EDG-5506 for the treatment of Duchenne muscular dystrophy (DMD).
• Shares of the clinical-stage biopharma earlier closed -5.8% at $9.34.
• The mid-stage trial, called LYNX, will look at the safety, pharmacokinetics and effect on biomarkers of muscle damage of EDG-5506 in children with DMD, EWTX said in a statement .
• The trial will assess the effect of three doses of EDG-5506 over 12 weeks. Approximately 27 children with DMD aged four to nine years are expected to be enrolled in the study.

For further details see: